InventisBio Co., Limited (SHA:688382)

Market Cap	12.73B +64.5%
Revenue (ttm)	180.53M +132.9%
Net Income	-116.28M
EPS	-0.20
Shares Out	578.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,447,640
Average Volume	13,677,311
Open	22.27
Previous Close	22.30
Day's Range	22.01 - 22.78
52-Week Range	12.32 - 49.68
Beta	0.17
RSI	27.69
Earnings Date	Mar 28, 2026

About InventisBio

InventisBio Co., Limited, a clinical stage biotech company, engages in the discovery and development of therapeutics for cancer and metabolic diseases in China. The company’s drug candidates for the oncology therapeutic area include BPI-D0316, which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Taragarestrant, which is in Phase III clinical trial for the treatment of estrogen receptor positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; and Gesorexel, which in Phase II cli...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 168
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688382

Financial Performance

In 2024, InventisBio's revenue was 168.79 million, a decrease of -9.02% compared to the previous year's 185.53 million. Losses were -240.20 million, -15.41% less than in 2023.